List of Excipients in Branded Drug LEVOPHED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	LEVOPHED	norepinephrine bitartrate	0409-0161	SODIUM CHLORIDE
Hospira Inc	LEVOPHED	norepinephrine bitartrate	0409-0161	SODIUM METABISULFITE
Hospira Inc	LEVOPHED	norepinephrine bitartrate	0409-3375	SODIUM CHLORIDE
Hospira Inc	LEVOPHED	norepinephrine bitartrate	0409-3375	SODIUM METABISULFITE
HF Acquisition Co LLC DBA HealthFirst	LEVOPHED(R) NOREPINEPHRINE BITARTRATE	levophed(r) norepinephrine bitartrate	51662-1315	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	LEVOPHED(R) NOREPINEPHRINE BITARTRATE	levophed(r) norepinephrine bitartrate	51662-1315	SODIUM METABISULFITE

LEVOPHED Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 8, 2026

LEVOPHED is an injectable norepinephrine product used to raise blood pressure in patients with severe, acute hypotension. Its commercial opportunity is driven less by active-ingredient innovation than by supply reliability, ready-to-use presentation, container compatibility, shortage resilience, and hospital workflow efficiency. The core product uses a simple excipient system, which lowers formulation complexity but increases competition from generic norepinephrine injections and premixed products.

What is LEVOPHED and which excipients does it contain?

LEVOPHED contains norepinephrine bitartrate, equivalent to norepinephrine base. The product is supplied as a sterile injectable solution for intravenous administration. The labeled formulation uses sodium chloride and Water for Injection, with pH adjustment using sodium hydroxide where required.[1]

Attribute	LEVOPHED profile
Active ingredient	Norepinephrine bitartrate
Active moiety	Norepinephrine
Dosage form	Sterile injectable solution
Route	Intravenous infusion after dilution or preparation according to labeling
Primary excipient	Sodium chloride
Vehicle	Water for Injection
pH control	Sodium hydroxide may be used for adjustment
Preservative status	Single-dose injectable presentation; preservative-free positioning is commercially relevant
Therapeutic class	Vasopressor
Primary setting	Intensive care, emergency medicine, operating rooms and acute-care hospitals
Regulatory pathway	Approved prescription injectable drug

Norepinephrine is chemically and physically sensitive to formulation conditions. The principal formulation variables are pH, oxidation control, light exposure, container compatibility, dilution medium, and storage time after preparation. The product label requires protection from light and identifies compatibility and administration constraints that affect hospital handling.[1]

Why is the excipient system strategically important?

The excipient burden is small, but formulation performance has a direct effect on product value. Hospitals prioritize:

• Stable potency during storage and administration.
• Low risk of discoloration or degradation.
• Compatibility with infusion bags, syringes and tubing.
• Simple preparation with fewer compounding steps.
• Reliable supply during critical-care demand spikes.
• Reduced medication-error risk.

A basic sodium chloride and Water for Injection formulation is difficult to differentiate through composition alone. Commercial differentiation therefore shifts toward concentration, packaging, shelf life, ready-to-use status, stability data, administration devices and supply assurance.

What formulations are protected by LEVOPHED-related patents?

Norepinephrine is an established active ingredient with a long history of clinical use. The original product and basic norepinephrine formulations are outside any practical period of composition-of-matter exclusivity. Current commercial protection is more likely to involve product-specific regulatory rights, manufacturing know-how, container systems, premixed presentations or privately held formulation patents rather than the active ingredient itself.

No active-ingredient patent barrier is identified in the FDA labeling and regulatory materials cited for the product.[1][2]

Are there formulation patents for norepinephrine injection?

Potential patentable areas include:

1. Stabilized norepinephrine solutions with controlled pH.
2. Premixed norepinephrine in dextrose or sodium chloride.
3. Low-sorption bags, syringes or infusion sets.
4. Oxygen-reduced or nitrogen-flushed containers.
5. Light-protective packaging.
6. Extended room-temperature stability.
7. High-concentration formulations that reduce fluid load.
8. Ready-to-administer systems that eliminate bedside dilution.
9. Combination container-closure and administration-device systems.

These claims can create commercial differentiation, but their enforceability depends on claim scope, prosecution history, priority dates, patent term and whether the product is covered by an Orange Book-listed patent. A formulation patent that covers only a narrow concentration or container configuration may not prevent competing norepinephrine products using a different presentation.

What is the Orange Book status of LEVOPHED?

LEVOPHED is an FDA-approved prescription injectable product. Orange Book analysis for a generic competitor requires review of the current reference-listed-drug entry, listed patents, exclusivity codes and any applicable FDA determinations.[2]

For an old injectable product, the main commercial question is usually not whether the active ingredient remains protected. It is whether a current listed patent or regulatory exclusivity could delay approval of an abbreviated new drug application, or ANDA.

Regulatory issue	Commercial implication
Active ingredient age	No practical new-molecule exclusivity
Product age	Generic competition is permitted if FDA requirements are met
Injectable dosage form	Manufacturing, sterility and stability requirements remain demanding
Orange Book patents	Must be assessed against the current listed reference product
Pediatric exclusivity	No product-specific extension should be assumed without an FDA listing
Orphan exclusivity	Not applicable to standard norepinephrine use
Biosimilar pathway	Not applicable because norepinephrine is a small molecule

LEVOPHED is not a biologic. Biosimilar risk does not apply. Competitive risk comes from generic injectable norepinephrine, premixed solutions and hospital-compounding alternatives.

When does LEVOPHED lose exclusivity?

The practical loss of exclusivity occurred long ago because norepinephrine injection is an established small-molecule product with generic versions available in the U.S. The relevant commercial exposure is therefore generic substitution and contracting pressure, not a future branded patent cliff.

The FDA’s generic-drug framework permits ANDA applicants to rely on the reference product’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence or other applicable requirements.[3] Injectable products may face limited conventional bioequivalence issues compared with oral drugs, but they still require compliance with quality, sterility, manufacturing, stability and labeling standards.

Do Paragraph IV challenges affect LEVOPHED?

A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable or will not be infringed. Its importance depends on whether relevant patents are listed for the reference product at the time of filing.[3]

For LEVOPHED, Paragraph IV risk is not the central market issue unless a current formulation, device or presentation patent is listed in the Orange Book. The stronger risks are:

• ANDA approval for conventional norepinephrine injection.
• Generic hospital contracts.
• Shortage-driven substitution.
• Premixed products that reduce preparation time.
• New container systems with improved stability.
• Institutional preference for ready-to-use vasopressors.

Which companies compete with LEVOPHED?

The competitive field includes the branded product, generic norepinephrine injection manufacturers, premixed intravenous suppliers and hospital pharmacy compounders.

Pfizer became the commercial owner of Hospira after completing its acquisition of the company in 2015. Hospira had been a major supplier of injectable hospital products, including norepinephrine presentations.[4]

Competitive segments

Segment	Product proposition	Main advantage
Branded LEVOPHED	Established reference product	Clinical familiarity and institutional recognition
Generic norepinephrine injection	Equivalent active ingredient and dosage form	Lower acquisition cost
Premixed norepinephrine bags	Ready-to-use infusion	Lower preparation burden and medication-error risk
Pharmacy-compounded product	Site-specific concentration and volume	Flexibility during shortages
Contract-manufactured injectable	Institutional or private-label supply	Procurement diversification
Device-enabled presentation	Syringe, cartridge or proprietary container	Workflow integration and differentiation

Brand strength is limited when hospitals use formulary substitution and group purchasing contracts. The brand can retain value where clinicians prefer a familiar product, where supply is constrained, or where procurement contracts reward dependable availability.

What excipient strategies create commercial opportunities?

Ready-to-use premixed products

The strongest near-term opportunity is a ready-to-use norepinephrine presentation. Premixed bags or syringes can reduce:

• Bedside dilution.
• Calculation errors.
• Manipulation of concentrated vials.
• Pharmacy workload.
• Time to vasopressor initiation.
• Variation between hospitals.

The formulation must maintain potency and appearance over the labeled shelf life and during the in-use period. Commercially attractive formats include standard hospital concentrations in sodium chloride or dextrose solutions, as well as lower-volume concentrated products for patients requiring fluid restriction.

Low-volume and high-concentration products

A concentrated norepinephrine product can reduce total infusion volume, which is relevant in intensive-care patients with fluid restrictions. The formulation opportunity is balanced against dosing-error risk and the need for clear labeling, dedicated administration protocols and compatible infusion equipment.

A successful product would require a concentration that is clinically useful without creating confusion with conventional presentations. Color-coded labels, barcode integration and standardized pump libraries may provide more commercial value than a novel excipient.

Container and tubing compatibility

Norepinephrine products can interact with administration materials through adsorption, absorption or chemical degradation. A differentiated product may use:

• Low-binding polymer bags.
• Compatible syringe materials.
• Protective overwraps.
• Light-resistant containers.
• Validated tubing sets.
• Lower oxygen-permeability packaging.

Container claims may be more defensible than broad claims covering norepinephrine and sodium chloride. The commercial value depends on evidence that the container maintains delivered dose and stability across the intended administration system.

Oxygen and oxidation control

Norepinephrine is susceptible to oxidative degradation. Manufacturers can evaluate headspace control, oxygen-reduced filling, nitrogen flushing, antioxidants and pH optimization. Any antioxidant strategy must be assessed against injectable safety, impurity formation, hypersensitivity concerns and regulatory acceptability.

A sulfite-based system may reduce oxidation but introduces a labeling and safety consideration for sulfite-sensitive patients. A product positioned as sulfite-free may have a marketing advantage if it can achieve equivalent stability through pH control, oxygen management and packaging.

Pediatric and neonatal presentations

Neonatal and pediatric intensive-care units require small volumes, precise dosing and flexible concentrations. Opportunities include:

• Low-fill-volume syringes.
• Standardized neonatal concentrations.
• Ready-to-administer syringes.
• Extended stability after opening or connection.
• Reduced dead-space delivery systems.

These products may support premium pricing if they reduce waste and preparation steps. They also face more stringent usability and dosing-error scrutiny.

What manufacturing and intellectual-property barriers exist?

Norepinephrine injection has a low active-ingredient barrier but a meaningful sterile-manufacturing barrier. Key requirements include:

• Aseptic processing or validated terminal sterilization where feasible.
• Sterility assurance.
• Endotoxin control.
• Particulate control.
• Accurate fill volume.
• Stability-indicating analytical methods.
• Control of oxidative impurities.
• Container-closure integrity.
• Extractables and leachables assessment.
• Validation of administration compatibility.

The main manufacturing risk is not chemical complexity. It is the combination of sterile injectable quality systems, reliable raw-material supply, fill-finish capacity and regulatory inspection readiness.

Supply concentration can create commercial opportunity. The FDA has identified recurring shortages across injectable hospital medicines, and the American Society of Health-System Pharmacists maintains shortage information used by hospitals and procurement organizations.[5][6] A norepinephrine supplier with multiple manufacturing sites, redundant fill-finish capacity and validated alternate components can gain share even without patent exclusivity.

What licensing deals could support a LEVOPHED opportunity?

Potential licensing structures include:

1. Licensing a premixed norepinephrine formulation to an established hospital-injectable company.
2. Acquiring rights to a low-sorption container or syringe system.
3. Partnering with a contract manufacturer that has sterile fill-finish capacity.
4. Licensing a formulation with extended room-temperature stability.
5. Co-developing a private-label product with a group purchasing organization supplier.
6. Combining a norepinephrine product with smart-pump or barcode-enabled administration technology.

The most valuable asset is likely to be a complete product platform rather than an excipient patent alone. A licensor with stability data, validated packaging, regulatory documentation and commercial-scale manufacturing has stronger negotiating leverage than one holding an early-stage formulation concept.

How strong is the LEVOPHED patent estate?

The patent estate for the basic LEVOPHED formulation is commercially weak because the active ingredient and conventional injectable dosage form are old. A new entrant can compete without inventing a novel molecule.

A differentiated formulation estate could be moderate if it combines:

• Narrow but enforceable composition claims.
• Container-specific claims.
• Administration-system claims.
• Strong stability data.
• Commercially relevant concentrations.
• Freedom to operate against prior art.
• Orange Book listing where legally available.

Patent strength should be evaluated claim by claim. Broad claims to norepinephrine in water or sodium chloride are vulnerable to prior-art challenges. More specific claims directed to impurity limits, oxygen control, container materials or extended stability may provide stronger but narrower protection.

What generic launch scenarios exist for LEVOPHED?

Conventional generic launch

A generic manufacturer launches a vial or ampule containing norepinephrine injection at a lower price. The product competes primarily through hospital contracts, supply reliability and regulatory approval.

Authorized or private-label launch

A major injectable supplier markets a product under a private label or distribution agreement. This can accelerate hospital adoption through an existing procurement network.

Premixed launch

A supplier introduces norepinephrine in a ready-to-use bag or syringe. The product may command a higher price than a conventional vial if it demonstrates reduced preparation time and lower medication-error exposure.

Shortage-driven launch

A manufacturer enters during a supply disruption. The opportunity can be significant, but a temporary shortage advantage does not ensure durable market share. Hospitals often retain alternate suppliers after a shortage if the new product has reliable quality and pricing.

Geographic expansion

Manufacturers may first target the U.S. hospital market, then pursue Canada, Europe, Japan, Australia or emerging markets. Each jurisdiction has distinct requirements for sterile manufacturing, labeling, concentration standards, reference products and pharmacopoeial compliance.

What is the revenue exposure for Pfizer and competing suppliers?

Public sources cited here do not provide a product-level revenue figure for LEVOPHED. The economic exposure is concentrated in hospital injectable procurement rather than retail pharmacy sales.

Revenue is affected by:

• Generic price erosion.
• Hospital contract renewals.
• Group purchasing organization terms.
• Product shortages.
• Premixed-product adoption.
• Manufacturing reliability.
• ICU and emergency-care demand.
• Conversion from branded vials to generic or ready-to-use products.

The highest-value commercial position is usually a reliable, differentiated presentation with lower preparation burden. A conventional vial without a supply or workflow advantage faces substantial price pressure.

Key Takeaways

• LEVOPHED is norepinephrine bitartrate injection, a mature small-molecule hospital product.
• Its basic formulation uses sodium chloride and Water for Injection, with pH adjustment as needed.
• The active ingredient has no practical remaining composition-of-matter exclusivity.
• Biosimilar risk does not apply; generic injectable competition is the relevant threat.
• Paragraph IV risk matters only if current Orange Book-listed patents cover the reference product.
• The strongest commercial opportunities are ready-to-use bags, prefilled syringes, low-volume concentrations and improved container systems.
• Oxidation control, light protection, tubing compatibility and stability are the main formulation priorities.
• Sterile fill-finish capacity and supply reliability are more important barriers than active-ingredient chemistry.
• A formulation patent alone may have limited value unless supported by regulatory approval, stability data and commercial manufacturing.
• Premixed norepinephrine products can capture value by reducing compounding steps and medication-error risk.

FAQs

Can sodium chloride be replaced in a norepinephrine formulation?

Yes, alternative diluents may be technically possible, including dextrose-based solutions, but each formulation requires independent stability, compatibility, sterility and regulatory evaluation. The commercial choice depends on clinical protocols, fluid-load considerations and hospital standardization.

Is a preservative useful in LEVOPHED-type injections?

Preservatives are generally unattractive for single-dose intravenous vasopressor products. A preservative-free presentation can simplify safety positioning and support use in critical-care and neonatal settings.

Can a new norepinephrine concentration receive meaningful patent protection?

Potentially, but concentration alone may be insufficient if it is obvious from prior art or clinically interchangeable with existing products. Stronger protection may combine concentration, stability performance, container materials and administration-system limitations.

Does a premixed norepinephrine bag require a new FDA application?

A materially different presentation may require a new or supplemental regulatory pathway, depending on the sponsor, reference product, formulation, manufacturing process and labeling differences. FDA requirements must be assessed under the applicable drug-approval pathway.

What is the most defensible commercial niche for a new norepinephrine product?

The most defensible niche is a ready-to-administer product with validated stability, low-sorption packaging, clear concentration standardization, reliable supply and integration with hospital medication systems.

References

1. U.S. Food and Drug Administration. (n.d.). LEVOPHED (norepinephrine bitartrate) injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. FDA.
4. Pfizer Inc. (2015). Pfizer completes acquisition of Hospira. Pfizer investor and corporate communications materials.
5. U.S. Food and Drug Administration. (n.d.). Drug shortages. FDA Drug Shortages Database.
6. American Society of Health-System Pharmacists. (n.d.). Drug shortages statistics and information. ASHP Drug Shortages Resource Center.